 NEW YORK, Aug. 24, 2022 GLOBE NEWSWIRE -- Immunovant, Inc. Nasdaq: IMVT, a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET. 